**Supplementary Table I – Details of Includes STAs**

|  |  |  |
| --- | --- | --- |
| STA # | Code | Title |
| 1 | TA492 | Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| 2 | TA493 | Cladribine tablets for treating relapsing–remitting multiple sclerosis |
| 3 | TA494 | Naltrexone–bupropion for managing overweight and obesity |
| 4 | TA495 | Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| 5 | TA496 | Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| 6 | TA483 | Nivolumab for previously treated squamous non-small-cell lung cancer |
| 7 | TA484 | Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| 8 | TA485 | Sarilumab for moderate to severe rheumatoid arthritis |
| 9 | TA487 | Venetoclax for treating chronic lymphocytic leukaemia |
| 10 | TA488 | Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| 11 | TA489 | Vismodegib for treating basal cell carcinoma |
| 12 | TA490 | Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| 13 | TA491 | Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| 14 | TA478 | Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| 15 | TA479 | Reslizumab for treating severe eosinophilic asthma |
| 16 | TA480 | Tofacitinib for moderate to severe rheumatoid arthritis |
| 17 | TA475 | Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| 18 | TA476 | Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| 19 | TA463 | Cabozantinib for previously treated advanced renal cell carcinoma |
| 20 | TA465 | Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| 21 | TA466 | Baricitinib for moderate to severe rheumatoid arthritis |
| 22 | TA467 | Holoclar for treating limbal stem cell deficiency after eye burns |
| 23 | TA471 | Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| 24 | TA472 | Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| 25 | TA456 | Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| 26 | TA457 | Carfilzomib for previously treated multiple myeloma |
| 27 | TA461 | Roflumilast for treating chronic obstructive pulmonary disease |
| 28 | TA462 | Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| 29 | TA446 | Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| 30 | TA447 | Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| 31 | TA448 | Etelcalcetide for treating secondary hyperparathyroidism |
| 32 | TA450 | Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| 33 | TA451 | Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| 34 | TA440 | Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
| 35 | TA442 | Ixekizumab for treating moderate to severe plaque psoriasis |
| 36 | TA443 | Obeticholic acid for treating primary biliary cholangitis |
| 37 | TA427 | Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| 38 | TA428 | Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| 39 | TA429 | Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| 40 | TA430 | Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| 41 | TA431 | Mepolizumab for treating severe refractory eosinophilic asthma |